1. Home
  2. HSBC vs GKOS Comparison

HSBC vs GKOS Comparison

Compare HSBC & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HSBC Holdings plc.

HSBC

HSBC Holdings plc.

HOLD

Current Price

$74.94

Market Cap

226.5B

Sector

Finance

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$109.19

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HSBC
GKOS
Founded
1865
1998
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Savings Institutions
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
226.5B
5.4B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
HSBC
GKOS
Price
$74.94
$109.19
Analyst Decision
Buy
Strong Buy
Analyst Count
3
13
Target Price
N/A
$123.62
AVG Volume (30 Days)
1.7M
846.3K
Earning Date
10-28-2025
10-29-2025
Dividend Yield
4.37%
N/A
EPS Growth
N/A
N/A
EPS
0.93
N/A
Revenue
$57,976,000,000.00
$469,820,000.00
Revenue This Year
$12.50
$31.15
Revenue Next Year
$2.06
$24.15
P/E Ratio
$80.68
N/A
Revenue Growth
0.01
30.38
52 Week Low
$45.66
$73.16
52 Week High
$75.44
$163.71

Technical Indicators

Market Signals
Indicator
HSBC
GKOS
Relative Strength Index (RSI) 67.11 70.89
Support Level $70.77 $105.88
Resistance Level $72.24 $110.87
Average True Range (ATR) 0.67 3.39
MACD 0.39 -0.04
Stochastic Oscillator 91.48 80.77

Price Performance

Historical Comparison
HSBC
GKOS

About HSBC HSBC Holdings plc.

Established in 1865 in Hong Kong, London-based HSBC is one of the largest banks in the world, with assets of USD 3 trillion and 40 million customers worldwide. It operates in more than 50 countries with more than 200,000 full-time staff. The United Kingdom and Hong Kong are its two largest markets. The bank offers retail, commercial and institutional banking, global banking and markets, wealth management, and private banking.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: